Startups

NBCL

nl.linkedin.com

NBCL (Novel Biomarkers Catalyst Lab) develops and manufactures point-of-care immunoassays and diagnostic instruments in Nijmegen, the Netherlands. Its CONNECT analyzer measures intact parathyroid hormone from a whole-blood sample in about five minutes, bringing biochemical information into the operating room during parathyroid surgery. Disposable cartridges, barcode scanning, calibration and quality controls support testing without routine sample preparation or a central laboratory workflow. The company also develops immunoassays and provides assay-development and production expertise. CONNECT is used in hospitals across Europe and other EMEA markets. Its US market entry remains under development, and NBCL states that its intraoperative PTH test is not FDA-cleared or approved for US sale. A separate EFRO-supported EAGLE-EYE application for rapid assessment of parathyroid function is still undergoing technological development and clinical validation.

Founded 2012

Team

Chris RosmalenPublished Professional Affiliation — exact current title unverified

Dominique ClarysseTeam Member and Conference Representative — exact rank unpublished

Edmond InsingerUS Market-development Representative — exact rank and employment unverified

Herbert TorfsCEO; Commercial Director (latter explicitly published December2025)

Matt ThomasonUK & Ireland National Sales Manager — published November2023; current title unverified

Rob LipsTeam Member and Conference Representative — exact rank unpublished

Robert van VlietHead of Global Marketing and Field Applications

Steven van LieropTechnical Director — published November2023; current tenure unverified

Investments

$—2025-12-10

ECFG

team@apexlogos.ai8 hours ago
Reviewed 8 October 2026. NBCL is the Nijmegen diagnostics business, expanded by its own website as Novel Biomarkers Catalyst Lab and identified in the footer as NBCL B.V. It is distinct from unrelated banking, building and architecture companies using NBCL. Own about and company profile agree on founding 2012. The current website address is Kerkenbos 1224; an older company-profile location remains Kerkenbos 1097-C. No legal incorporation day, subsidiary or regulatory licence is inferred. All 12 pages in the current issuer sitemap were fetched, alongside named staff announcements and public primary professional profiles. The issuer does not publish a complete current staff or board roster. The eight recovered named affiliations are individually scoped: current own event leadership, exact dated appointments, named company representatives, or a self-published professional affiliation with unknown rank. Herbert Torfs is the currently published CEO; the December2025 release also names Commercial Director. Robert van Vliet’s exact global marketing and field-applications title is published on the May2026 event page. Rob Lips and Dominique Clarysse are expressly named colleagues and representatives, without an inferred higher rank. Edmond Insinger’s representative visit does not establish an employee, legal director or investing owner. Steven van Lierop and Matt Thomason retain the dates and tenure uncertainty of their original announcements. Chris Rosmalen’s primary profile proves a professional affiliation, while an outdated secondary CEO title is not applied. Nils Clausnitzer appears only in an automatically attributed employee list without a recovered primary role; he remains queued. Michael Jansen’s secondary CTO lead remains unverified. No full 30-person team claim, clinical-author employment, or investor identity is derived from company tags or testimonials. The investment release has a signed dateline of 10 December 2025 and a public CMS header of 15 December 2025. The record uses the explicit release milestone and preserves both dates. ECFG invests through existing Ventures III, CGZJAXY1BZBS2TN58BCSK3YP2AKFG895, and the actual participation belongs to existing manager 11007. Amount, stage, ticket and lead status are undisclosed. An unnamed Dutch medical-technology co-investor, management and existing shareholders are mentioned, but no names or personal subscriptions are inferred. No allocation is inferred from Edmond Insinger’s separate professional context. There is no extra fund, duplicate round, or guessed participant. EFRO Oost support for EAGLE-EYE is a separate research-project instrument: no public cash amount or exact award date was recovered, so no financing round or investor participation is created for it. CONNECT’s five-minute intraoperative PTH testing and EMEA hospital deployment are distinct from the EAGLE-EYE application, which remains in development and clinical validation. The issuer explicitly states its intraoperative PTH test is not FDA-cleared or approved and not offered for sale in the United States. US clinical studies and market-development visits are not approval. Original clinical papers document comparison with laboratory assays and potential false results; manufacturer efficiency and patient-benefit statements are not universal guarantees. No CE class, approval number or unconditional diagnostic accuracy claim is added. The authentic red NBCL header wordmark is preserved unchanged and visually inspected.